Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339571 · ClinicalTrials.gov registry record · Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
A Phase 2 study of Stage IV Cutaneous Melanoma AJCC v6 and v7 and Stage III Cutaneous Melanoma AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT02339571 is a Phase 2 study of Stage IV Cutaneous Melanoma AJCC v6 and v7 and Stage III Cutaneous Melanoma AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 600 participants, above the 171-participant average among 17 other Stage IV Cutaneous Melanoma AJCC v6 and v7 trials with a reported enrollment target (251% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02339571, a Phase 2 study of Stage IV Cutaneous Melanoma AJCC v6 and v7 and Stage III Cutaneous Melanoma AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Echocardiography Test
- BIOLOGICAL Ipilimumab
- PROCEDURE Magnetic Resonance Elastography
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- PCR Oncology - Arroyo Grande
- Sutter Auburn Faith Hospital - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills-Peninsula Medical Center - Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Eden Hospital Medical Center - Castro Valley
- Sutter Davis Hospital - Davis
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
Arkansas
- CARTI Cancer Center - Little Rock
- John L McClellan Memorial Veterans Hospital - Little Rock
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arizona
- Kingman Regional Medical Center - Kingman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2033-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339571
The ClinicalTrials.gov registry entry for NCT02339571 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 171-participant average among 17 other Stage IV Cutaneous Melanoma AJCC v6 and v7 trials with a reported enrollment target (251% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Cutaneous Melanoma AJCC v6 and v7 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02339571 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT02339571 about?
NCT02339571 is a clinical study titled "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma". This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first st...
What is the current status of trial NCT02339571?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2015-11-23. Estimated completion is 2033-06-30.
What conditions does trial NCT02339571 study?
This clinical trial studies the following conditions: Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage III Cutaneous Melanoma AJCC v7.
What interventions are being tested in trial NCT02339571?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Echocardiography Test (PROCEDURE), Ipilimumab (BIOLOGICAL), Magnetic Resonance Elastography (PROCEDURE).
Who is sponsoring clinical trial NCT02339571?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02339571 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Cutaneous Melanoma AJCC v6 and v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
ACTIVE NOT RECRUITING · Phase 2
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Cutaneous Melanoma AJCC v6 and v7
All registered trials for this condition
Stage III Cutaneous Melanoma AJCC v7
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.